Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954088396> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2954088396 abstract "Background and Aim: Triple-negative breast cancer (TNBC) is a very aggressive subtype of breast cancer characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor expression. Mortality from TNBC is significantly higher in African American (AA) women in comparison to European American (EA) women (5-year relative survival of only 14% for AA in comparison to 36% for EA) even though the incidence rates are lower in AA women. Irrespective of stage at diagnosis, AA-TNBC is more aggressive with higher metastasis and a poorer survival than EA-TNBC; therefore, it is imperative to understand the molecular determinants that drive aggressive progression of AA-TNBC. Overall aim of this study is to decipher the alterations in the molecular circuitry underlying racial disparity in TNBC progression in AA women compared to EA women. Results: AA-TNBC cells (HCC1806 and HCC1569) exhibited increased growth and higher migration potential; higher expression of stemness factors, increased number of mammospheres and higher CD44+/CD49f+ population in comparison to EA-TNBC (Hs578t, BT549, HCC1937 and HCC1187) cells. We analyzed RNA sequencing data of multiple AA and EA TNBC cell lines for self-renewal pathways (Wnt/βCatenin, GLI1/Shh and YAP-TAZ) and observed significantly higher levels of GLI1 in AA-TNBC cell lines while no significant alterations were observed in other pathway components. Further analysis of TCGA dataset revealed a positive correlation between GLI1 and Notch1 in AA-TNBC with a negative correlation in EA-TNBC. Increased expression of components of GLI1 and Notch1 pathway (SHH, Jagged, cleaved-Notch (NICD), Hes1 and FOXM1) were noted in AA-TNBC compared to EA-TNBC cells. AA-TNBC cells showed increased nuclear localization of GLI1 and NICD as compared to EA-TNBC cells. We observed that GLI and NICD co-localize in AA-TNBC. High expression of GLI1 and Notch1 correlated with poor overall survival in TNBC patients. AA TNBC Tumor samples show higher expression of GLI1 and NICD in comparison to TNBC tumors from EA patients. Concomitant inhibition of GLI1 and Notch1 using respective small molecule inhibitors, GANT61 and DAPT, along with standard chemotherapeutic agents (Doxorubicin and carboplatin) effectively inhibited AA TNBC growth and progression in mice; growth, proliferation, migration and invasion of ex vivo tumor cells and downregulated CD44+/CD49f+ and ADLH1A1+ population in a synergistic manner. Combined treatment with GANT61+ DAPT+ Carboplatin effectively reduced stem cell frequency of AA-TNBC tumors in in vivo limiting dilution assay. Conclusions: In conclusion, these results show that AA-TNBC cells are inherently aggressive with increased growth, migration and stemness potential. We found aberrant activation of GLI and Notch pathway and a crosstalk between GLI1 and NICD whose inhibition effectively inhibits AA-TNBC and sensitizes AA-TNBC to standard chemotherapy.Citation Format: Sumit Siddharth, Anirudh Saxena, Nethaji Muniraj, Sheetal Parida, Arumugam Nagalingam, Dipali Sharma. Aberrant activation of GLI1 and Notch1 contributes to racial disparity in triple-negative breast cancer progression [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr LB-222." @default.
- W2954088396 created "2019-07-12" @default.
- W2954088396 creator A5008199197 @default.
- W2954088396 creator A5008586835 @default.
- W2954088396 creator A5030200822 @default.
- W2954088396 creator A5031647936 @default.
- W2954088396 creator A5035543524 @default.
- W2954088396 creator A5052903439 @default.
- W2954088396 date "2020-08-13" @default.
- W2954088396 modified "2023-10-14" @default.
- W2954088396 title "Abstract LB-222: Aberrant activation of GLI1 and Notch1 contributes to racial disparity in triple-negative breast cancer progression" @default.
- W2954088396 doi "https://doi.org/10.1158/1538-7445.am2020-lb-222" @default.
- W2954088396 hasPublicationYear "2020" @default.
- W2954088396 type Work @default.
- W2954088396 sameAs 2954088396 @default.
- W2954088396 citedByCount "0" @default.
- W2954088396 crossrefType "proceedings-article" @default.
- W2954088396 hasAuthorship W2954088396A5008199197 @default.
- W2954088396 hasAuthorship W2954088396A5008586835 @default.
- W2954088396 hasAuthorship W2954088396A5030200822 @default.
- W2954088396 hasAuthorship W2954088396A5031647936 @default.
- W2954088396 hasAuthorship W2954088396A5035543524 @default.
- W2954088396 hasAuthorship W2954088396A5052903439 @default.
- W2954088396 hasConcept C121608353 @default.
- W2954088396 hasConcept C126322002 @default.
- W2954088396 hasConcept C137620995 @default.
- W2954088396 hasConcept C143998085 @default.
- W2954088396 hasConcept C1491633281 @default.
- W2954088396 hasConcept C2779933373 @default.
- W2954088396 hasConcept C2780110267 @default.
- W2954088396 hasConcept C2780932548 @default.
- W2954088396 hasConcept C2908647359 @default.
- W2954088396 hasConcept C502942594 @default.
- W2954088396 hasConcept C530470458 @default.
- W2954088396 hasConcept C54355233 @default.
- W2954088396 hasConcept C55493867 @default.
- W2954088396 hasConcept C62478195 @default.
- W2954088396 hasConcept C71924100 @default.
- W2954088396 hasConcept C84606932 @default.
- W2954088396 hasConcept C86803240 @default.
- W2954088396 hasConcept C88498014 @default.
- W2954088396 hasConcept C98717036 @default.
- W2954088396 hasConcept C99454951 @default.
- W2954088396 hasConceptScore W2954088396C121608353 @default.
- W2954088396 hasConceptScore W2954088396C126322002 @default.
- W2954088396 hasConceptScore W2954088396C137620995 @default.
- W2954088396 hasConceptScore W2954088396C143998085 @default.
- W2954088396 hasConceptScore W2954088396C1491633281 @default.
- W2954088396 hasConceptScore W2954088396C2779933373 @default.
- W2954088396 hasConceptScore W2954088396C2780110267 @default.
- W2954088396 hasConceptScore W2954088396C2780932548 @default.
- W2954088396 hasConceptScore W2954088396C2908647359 @default.
- W2954088396 hasConceptScore W2954088396C502942594 @default.
- W2954088396 hasConceptScore W2954088396C530470458 @default.
- W2954088396 hasConceptScore W2954088396C54355233 @default.
- W2954088396 hasConceptScore W2954088396C55493867 @default.
- W2954088396 hasConceptScore W2954088396C62478195 @default.
- W2954088396 hasConceptScore W2954088396C71924100 @default.
- W2954088396 hasConceptScore W2954088396C84606932 @default.
- W2954088396 hasConceptScore W2954088396C86803240 @default.
- W2954088396 hasConceptScore W2954088396C88498014 @default.
- W2954088396 hasConceptScore W2954088396C98717036 @default.
- W2954088396 hasConceptScore W2954088396C99454951 @default.
- W2954088396 hasLocation W29540883961 @default.
- W2954088396 hasOpenAccess W2954088396 @default.
- W2954088396 hasPrimaryLocation W29540883961 @default.
- W2954088396 hasRelatedWork W2050936961 @default.
- W2954088396 hasRelatedWork W2370952237 @default.
- W2954088396 hasRelatedWork W2375815296 @default.
- W2954088396 hasRelatedWork W2497974553 @default.
- W2954088396 hasRelatedWork W25085055 @default.
- W2954088396 hasRelatedWork W2550669964 @default.
- W2954088396 hasRelatedWork W2584184160 @default.
- W2954088396 hasRelatedWork W2953241133 @default.
- W2954088396 hasRelatedWork W3198519606 @default.
- W2954088396 hasRelatedWork W4205578220 @default.
- W2954088396 isParatext "false" @default.
- W2954088396 isRetracted "false" @default.
- W2954088396 magId "2954088396" @default.
- W2954088396 workType "article" @default.